Single-Site Mutational Engineering and Following MonoPEGylation of the Human Lectin Galectin-2: Effects on Ligand Binding, Functional Aspects, and Clearance from Serum

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10174088" target="_blank" >RIV/00216208:11110/13:10174088 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.1021/mp4000629" target="_blank" >http://dx.doi.org/10.1021/mp4000629</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1021/mp4000629" target="_blank" >10.1021/mp4000629</a>

Result language

angličtina

Original language name

Single-Site Mutational Engineering and Following MonoPEGylation of the Human Lectin Galectin-2: Effects on Ligand Binding, Functional Aspects, and Clearance from Serum

Original language description

The emerging insights into the physiological significance of endogenous lectins prompted us to characterize the effect of monosubstitution with poly(ethylene glycol) (PEG; 5 kDa) on a human lectin. As role model, we used a member of the galectin family,that is, galectin-2, the Cys57Met (single-site) mutant and its monoPEGylated derivative. The activities of these three proteins were comparatively studied by biochemical, cell biological, and histochemical methods, using surface-immobilized glycoproteins, different types of cells presenting gangliosides or (glyco)proteins as counterreceptors in vitro and tissue sections. PEGylation led to decreases in affinity/signal intensity with context dependence. The introduction of the mutation, too, can influencereactivity. Assays on haemagglutination and inhibition of cell proliferation underscored that mutational engineering and substitution can (but must not necessarily) affect this protein's activity. Serum clearance in rats was markedly ret

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

CE - Biochemistry

OECD FORD branch

—

Project

—

Continuities

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2013

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Molecular Pharmaceutics

ISSN

1543-8384

e-ISSN

—

Volume of the periodical

10

Issue of the periodical within the volume

5

Country of publishing house

US - UNITED STATES

Number of pages

8

Pages from-to

2054-2061

UT code for WoS article

000318669600053

EID of the result in the Scopus database

—